Samba records sales of KRW 900 billion in the first quarter… Achieved best performance ever

Samsung BioLogics achieved its highest ever sales in the first quarter (January to March). It is interpreted that this is a result that reflects the sales of Factory 4, which began full operation in June of last year.

According to information announced by Samsung BioLogics on the 24th, sales in the first quarter were KRW 946.9 billion, a 31% increase compared to the same period last year (KRW 720.9 billion). Operating profit was 221.3 billion won, an increase of 15% compared to the same period last year (191.7 billion won). Both sales and operating profit are the highest ever in the first quarter.

What drove the increase in sales this year was Factory 4, which began full operation in June of last year. The production volume of Factory 4 is 240,000 liters, which is the largest for a single factory. The company explained that the operation rate of Factory 4 is gradually increasing.

Currently, Samsung BioLogics is constructing Plant 5 with the goal of completion in April next year. Factory 5 is a 180,000 L production plant that integrates the best practices of factories 1 to 4. The company plans to build factories 6 to 8 with the same design as factory 5, as if stamping them, and quickly expand production scale. When Factory 5 is completed, Samsung BioLogics’ production capacity will total 784,000L.

The progress of Samsung Bioepis, a subsidiary of Samsung BioLogics, is also notable. Samsung Bioepis’ first quarter sales were KRW 280.1 billion and operating profit was KRW 38.1 billion, up 31% and 6%, respectively, compared to the same period last year. Samsung Bioepis, which develops and sells biosimilars, explained that sales have increased in overseas markets such as the United States and Europe.

The company currently has 11 types of biosimilar products and sells 7 types of products in the global market, including Enbrel, a psoriasis treatment, and Humira, an autoimmune disease treatment. We are also developing a biosimilar of the cancer immunotherapy drug Keytruda, the world’s No. 1 drug in terms of sales, and plan to gradually strengthen our portfolio.

Reporter Choi Ji-won [email protected]